the future of inhibiting bcl2 for the treatment of t-all
Published 7 years ago • 120 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
2:30
novel bcl-2 & bcl-2/bclxl inhibitors emerging for the treatment of hematological malignancies
-
1:27
advances in btk and bcl2 inhibitors for cll
-
1:13
dual-targeted regimens for the treatment of cll: anti-cd20 antibodies, btki, and bcl2i
-
3:09
bcl2 inhibition and cll: the role of venetoclax
-
1:41
dual inhibition of bcl2 and mcl1 using tumor targeted nanoparticles in lymphoma
-
1:10
targeting apoptosis - developing drugs to inhibit bcl-2 and mcl-1
-
3:08
looking beyond bcl-2 inhibition in aml: the potential role of mcl-1 inhibitors and bclxl inhibitors
-
3:12
btk and bcl2 inhibitor resistance in cll: session highlights
-
30:17
writing the future of biologics by integrating immunization, libraries, and machine learning
-
12:07
1 7 lecture 6 the bcl 2 superfamily 12 06
-
1:20:43
the bcl2 protein family; structure and mechanism of apoptotic cell death
-
8:31
targeting bcl-2 in mds
-
1:20
improving outcomes of non-covalent btki treatment
-
9:35
treatment-changing advancements in cll: btk, bcl-2, cd20 & car t-cells
-
2:37
identifying human cancers to target with bcl-2 inhibition
-
1:14
novel inducers of apoptosis in double-refractory cll cells
-
2:41
an overview of the latest advances in hematology
-
1:09
the main aims of the t2evolve consortium
-
1:27
managing cardiotoxicity associated with the use of ibrutinib
-
1:34
the future role of ai models in hematology and the need for high-quality data sets
-
7:25
ai in hematology: advances, challenges, and future applications
-
4:16
the novel bioactive peptide qub-2392 shows anti-leukemic effects in leukemia cell lines